Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis $13.79 -0.36 (-2.54%) (As of 10:52 AM ET) Add Compare Share Share Today's Range$13.76▼$14.1250-Day Range$11.78▼$15.0652-Week Range$11.09▼$22.11Volume208,106 shsAverage Volume1.71 million shsMarket Capitalization$1.47 billionP/E Ratio26.52Dividend YieldN/APrice Target$24.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Catalyst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside74.9% Upside$24.75 Price TargetShort InterestBearish7.27% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.50Based on 10 Articles This WeekInsider TradingSelling Shares$569,600 Sold Last QuarterProj. Earnings Growth42.50%From $1.60 to $2.28 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.75 out of 5 starsMedical Sector69th out of 942 stocksPharmaceutical Preparations Industry15th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.75, Catalyst Pharmaceuticals has a forecasted upside of 74.9% from its current price of $14.15.Amount of Analyst CoverageCatalyst Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.27% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 3.74%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 2.5 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Catalyst Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 10 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows9 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $569,600.00 in company stock.Percentage Held by Insiders12.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.27% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 42.50% in the coming year, from $1.60 to $2.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 27.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 27.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.71.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Stock News HeadlinesDecember 10, 2023 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $569,600.00 in StockDecember 9, 2023 | finance.yahoo.comInsider Sell Alert: Chief Med. & Reg.December 11, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 8, 2023 | finance.yahoo.comWhy Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?December 8, 2023 | americanbankingnews.comBrokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) PT at $24.75December 5, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap CompaniesDecember 4, 2023 | bizjournals.comCatalyst Pharmaceuticals names new C-suite executives amid leadership reshuffleDecember 4, 2023 | markets.businessinsider.comCatalyst Pharma Names Michael Kalb CFO Effective Jan. 1, Succeeding Alicia GrandeDecember 11, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 4, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive PromotionsDecember 3, 2023 | investing.comCatalyst Pharmaceuticals (CPRX) Earnings Dates & ReportsNovember 16, 2023 | finance.yahoo.comCatalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare ConferenceNovember 10, 2023 | finance.yahoo.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | benzinga.comRecap: Catalyst Pharmaceuticals Q3 EarningsNovember 8, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate UpdateNovember 5, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Inc (CN2.DU)November 2, 2023 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 ReleaseNovember 2, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®October 31, 2023 | seekingalpha.comCatalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying OpportunityOctober 30, 2023 | finance.yahoo.comInstitutional owners may take dramatic actions as Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) recent 4.2% drop adds to one-year lossesOctober 28, 2023 | finanznachrichten.deCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSEOctober 23, 2023 | finance.yahoo.comCatalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023October 20, 2023 | marketwatch.comCatalyst Pharmaceuticals Director to Succeed Retiring CEOOctober 19, 2023 | bizjournals.comPharmaceutical company names former AstraZeneca exec new CEO, founder to retireOctober 19, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive OfficerOctober 16, 2023 | finance.yahoo.comPatrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFloridaOctober 14, 2023 | finance.yahoo.comThose who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) three years ago are up 291%See More Headlines Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees82Year Founded2002Price Target and Rating Average Stock Price Target$24.75 High Stock Price Target$27.00 Low Stock Price Target$24.00 Potential Upside/Downside+79.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.52 Trailing P/E Ratio26.52 Forward P/E Ratio8.62 P/E GrowthN/ANet Income$83.08 million Net Margins17.81% Pretax Margin23.20% Return on Equity19.32% Return on Assets16.00% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.17 Sales & Book Value Annual Sales$214.20 million Price / Sales6.86 Cash Flow$0.78 per share Price / Cash Flow17.66 Book Value$2.89 per share Price / Book4.77Miscellaneous Outstanding Shares106,610,000Free Float93,711,000Market Cap$1.47 billion OptionableOptionable Beta1.11 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Patrick J. McEnany (Age 76)Co-Founder, Chairman, President & CEO Comp: $1.2MMs. Alicia Grande C.M.A. (Age 52)CPA, Chief Accounting Officer, VP, Treasurer & CFO Comp: $667.91kDr. Steven R. Miller Ph.D. (Age 61)COO & Chief Scientific Officer Comp: $809.03kDr. Gary Ingenito M.D. (Age 67)Ph.D., Chief Medical & Regulatory Officer Comp: $751.85kMr. Jeffrey Del Carmen (Age 52)Chief Commercial Officer Comp: $711.7kMs. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 59)Chief Compliance Officer & Chief Legal Officer Comp: $311.42kMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D.Ph.D., Senior Vice President of Medical Affairs & Drug DiscoveryDr. Preethi Sundaram Ph.D. (Age 47)Chief Strategy Officer Comp: $511.25kMore ExecutivesKey CompetitorsCelldex TherapeuticsNASDAQ:CLDXDisc MedicineNASDAQ:IRONSpringWorks TherapeuticsNASDAQ:SWTXEQRxNASDAQ:EQRXGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPBought 100,000 shares on 12/7/2023Ownership: 0.281%Citigroup Inc.Sold 28,081 shares on 12/6/2023Ownership: 0.242%Steve MillerSold 40,000 sharesTotal: $569,600.00 ($14.24/share)American Century Companies Inc.Bought 153,697 shares on 11/30/2023Ownership: 0.844%Deutsche Bank AGSold 854,991 shares on 11/24/2023Ownership: 0.100%View All Insider TransactionsView All Institutional Transactions CPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price target for 2024? 4 analysts have issued 1 year price targets for Catalyst Pharmaceuticals' shares. Their CPRX share price targets range from $24.00 to $27.00. On average, they expect the company's stock price to reach $24.75 in the next twelve months. This suggests a possible upside of 74.9% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2023? Catalyst Pharmaceuticals' stock was trading at $18.60 on January 1st, 2023. Since then, CPRX stock has decreased by 23.9% and is now trading at $14.15. View the best growth stocks for 2023 here. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our CPRX earnings forecast. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). The biopharmaceutical company had revenue of $102.69 million for the quarter, compared to analysts' expectations of $100.17 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 19.32% and a net margin of 17.81%. What ETFs hold Catalyst Pharmaceuticals' stock? ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.35%), Jacobs Levy Equity Management Inc. (1.23%), LSV Asset Management (1.16%), Invesco Ltd. (0.96%), Charles Schwab Investment Management Inc. (0.86%) and American Century Companies Inc. (0.84%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CPRX) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.